A Phase 1 interventional study of BIBF 1120 in Neoplasms, sponsored by Boehringer Ingelheim. Completed at 11 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-12-02.
Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary objective of this trial is to evaluate the long-term safety of BIBF 1120 in terms of incidence and intensity of Adverse Events and changes in safety laboratory parameters.
Secondary objectives are the collection of further safety data (vital signs), efficacy data and the determination of pharmacokinetic characteristics during long-term therapy with BIBF 1120.
10,834 studies on the registry are indexed under Neoplasms; 2,323 are open to participants now.
This study's enrollment of 41 is below the median of 60 across 7,714 interventional studies indexed under Neoplasms.
Browse Neoplasms studies →Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Incidence and Intensity of Adverse Events With Highest CTCAE Grade 1
All patients who had grade 1 adverse events (AEs) as the worst grade of the AE. Incidence and intensity of Adverse Events with grading of Adverse Events according to Common Terminology Criteria for Adverse Events (CTCAE).
Time frame: From signing the informed consent until final follow-up, up to 991 days
Incidence and Intensity of Adverse Events With Highest CTCAE Grade 2
All patients who had grade 2 adverse events (AEs) as the worst grade of the AE. Incidence and intensity of Adverse Events with grading of Adverse Events according to Common Terminology Criteria for Adverse Events (CTCAE).
Time frame: From signing the informed consent until final follow-up, up to 991 days
Incidence and Intensity of Adverse Events With Highest CTCAE Grade 3
All patients who had grade 3 adverse events (AEs) as the worst grade of the AE. Incidence and intensity of Adverse Events with grading of Adverse Events according to Common Terminology Criteria for Adverse Events (CTCAE).
Time frame: From signing the informed consent until final follow-up, up to 991 days
Incidence and Intensity of Adverse Events With Highest CTCAE Grade 4
All patients who had grade 4 adverse events (AEs) as the worst grade of the AE. Incidence and intensity of Adverse Events with grading of Adverse Events according to Common Terminology Criteria for Adverse Events (CTCAE).
Time frame: From signing the informed consent until final follow-up, up to 991 days
Incidence and Intensity of Adverse Events With Highest CTCAE Grade 5
All patients who had grade 5 adverse events (AEs) as the worst grade of the AE. Incidence and intensity of Adverse Events with grading of Adverse Events according to Common Terminology Criteria for Adverse Events (CTCAE).
Time frame: From signing the informed consent until final follow-up, up to 991 days
Difference From Baseline for Liver Enzymes
Difference from baseline (normalized value). Baseline was defined as the value at the time point closest to but prior to very first administration of trial medication. The standard error is actually the Interquartile Range calculated as P75 minus P25.
Time frame: From signing the informed consent until end of treatment, up to 991 days
Difference From Baseline for Bilirubin, Creatinine and Glucose
Difference from baseline (normalized value). Baseline was defined as the value at the time point closest to but prior to very first administration of trial medication. The standard error is actually the Interquartile Range calculated as P75 minus P25.
Time frame: From signing the informed consent until end of treatment, up to 991 days
Difference From Baseline for Haemoglobin
Difference from baseline for Haemoglobin (normalized value). Baseline was defined as the value at the time point closest to but prior to very first administration of trial medication. The standard error is actually the Interquartile Range calculated as P75 minus P25.
Time frame: From baseline until end of treatment, up to 991 days
Difference From Baseline for Haematology and Differentials Parameters
Difference from baseline (normalized value). Baseline was defined as the value at the time point closest to but prior to very first administration of trial medication. The standard error is actually the Interquartile Range calculated as P75 minus P25.
Time frame: From signing the informed consent until end of treatment, up to 991 days
Difference From Baseline for Coagulation Parameters
Difference from baseline (normalized value) in coagulation parameters Prothrombin time, international normalised ratio (PT-INR) and partial thromboplastin time. Baseline was defined as the value at the time point closest to but prior to very first administration of trial medication. The standard error is actually the Interquartile Range calculated as P75 minus P25.
Time frame: From signing the informed consent until end of treatment, up to 991 days
Difference From Baseline for Electrolytes
Difference from baseline (normalized value). Baseline was defined as the value at the time point closest to but prior to very first administration of trial medication. The standard error is actually the Interquartile Range calculated as P75 minus P25.
Time frame: From signing the informed consent until end of treatment, up to 991 days
Clinically Relevant Abnormalities for Vital Signs
Clinically relevant abnormalities for Vital Signs (systolic blood pressure, diastolic blood pressure, and pulse rate). New abnormal findings or worsening of baseline conditions were reported as Adverse Events.
Time frame: From baseline until final follow-up, up to 991 days
Pre-dose Concentration of Nintedanib in Plasma at Steady-state (Cpre,ss)
Cpre,ss represents the pre-dose concentration of Nintedanib in Plasma at steady-state at day 29
Time frame: Just before drug administration every 28±7 days after day 29
Unconfirmed Best Overall Response
Unconfirmed best overall response assessed by RECIST (Response Evaluation Criteria In Solid Tumours) criteria (version 1.0). PD = Progressive disease.
Time frame: Baseline until end of treatment, up to 991 days
Unconfirmed Best Objective Response
Unconfirmed best objective response assessed by RECIST (Response Evaluation Criteria In Solid Tumours) criteria (version 1.0)
Time frame: Baseline until end of treatment, up to 991 days
Clinical Benefit
Clinical benefit was defined as the absence of disease progression (no PD or nonevaluable clinically progressive disease) determined by RECIST (version 1.0).
Time frame: Baseline until end of treatment, up to 991 days
Confirmed Objective Response
Confirmed objective response assessed by RECIST (Response Evaluation Criteria In Solid Tumours) criteria (version 1.0)
Time frame: Baseline until end of treatment, up to 991 days
Progression Free Survival
Percentage of participants that experienced progression free survival (PFS), assessed by RECIST (Response Evaluation Criteria In Solid Tumours) (version 1.0), by day 1230. Progression was defined as progressive disease (PD) or non-evaluable clinically progressive disease. PFS was defined for patients without PD at screening as the time from first treatment with the trial drug in the previous trial until onset of PD or death, whatever comes earlier. Patients with PD could enter the trial if they showed signs of clinical benefit. For patients with PD at screening, the RECIST assessment at screening was used as a new baseline value and PFS was the time from first treatment with the trial drug in this trial until the onset of progressive disease in this trial or death, whatever comes first.
Time frame: First drug administration (in previous trial) until end of treatment, up to 1230 days
This was a multinational, open-label, uncontrolled, extension trial with Nintedanib in patients who had experienced a clinical benefit with Nintedanib (objective tumour response or disease stabilisation and/or symptom improvement) in either one out of five phase I or phase I/IIA clinical trials for advanced solid tumours at study entry.
| Milestone | 50mg QD | 200mg QD | 100mg BID | 150mg BID | 200mg BID | 250mg BID | 300mg BID |
|---|---|---|---|---|---|---|---|
| Started | 1 | 1 | 4 | 9 | 6 | 19 | 1 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 1 | 1 | 4 | 9 | 6 | 19 | 1 |
| Withdrew: Progressive disease | 0 | 1 | 3 | 9 | 5 | 14 | 1 |
| Withdrew: Dose limiting toxicity (dlt) | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Other adverse event than dlt | 1 | 0 | 0 | 0 | 0 | 2 | 0 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Other reason not defined above | 0 | 0 | 1 | 0 | 1 | 1 | 0 |
All patients who had grade 1 adverse events (AEs) as the worst grade of the AE. Incidence and intensity of Adverse Events with grading of Adverse Events according to Common Terminology Criteria for Adverse Events (CTCAE).
| percentage of participants | 50mg QD | 200mg QD | 100mg BID | 150mg BID | 200mg BID | 250mg BID | 300mg BID |
|---|---|---|---|---|---|---|---|
| Dyspepsia | 100 | 0 | 0 | 11 | 0 | 0 | 0 |
| Fatigue | 100 | 0 | 0 | 33 | 17 | 0 | 0 |
| Nasopharyngitis | 100 | 0 | 0 | 0 | 33 | 5 | 0 |
| Anorexia | 100 | 0 | 0 | 11 | 0 | 16 | 0 |
| Hyperhidrosis | 100 | 0 | 0 | 11 | 0 | 5 | 0 |
| Diarrhoea | 0 | 100 | 0 | 44 | 50 | 37 | 100 |
| Bronchitis | 0 | 100 | 0 | 0 | 0 | 0 | 0 |
| Eye disorder | 0 | 0 | 25 | 0 | 0 | 0 | 0 |
| Eyelid oedema | 0 | 0 | 25 | 0 | 0 | 0 | 0 |
| Haemorrhoids | 0 | 0 | 25 | 0 | 0 | 5 | 0 |
| Toothache | 0 | 0 | 25 | 0 | 0 | 0 | 0 |
| Pyrexia | 0 | 0 | 25 | 11 | 17 | 5 | 0 |
| Muscle spasms | 0 | 0 | 25 | 11 | 0 | 11 | 0 |
| Neck pain | 0 | 0 | 25 | 0 | 0 | 0 | 0 |
| Pain in extremity | 0 | 0 | 25 | 11 | 17 | 5 | 0 |
| Vulvovaginal dryness | 0 | 0 | 25 | 0 | 0 | 0 | 0 |
| Arrhythmia | 0 | 0 | 0 | 11 | 0 | 0 | 0 |
| Nausea | 0 | 0 | 0 | 33 | 67 | 21 | 0 |
| Vomiting | 0 | 0 | 0 | 22 | 33 | 5 | 0 |
| Abdominal pain | 0 | 0 | 0 | 11 | 33 | 11 | 0 |
| Gastrooesophageal reflux disease | 0 | 0 | 0 | 11 | 0 | 0 | 0 |
| Tooth discolouration | 0 | 0 | 0 | 11 | 0 | 0 | 0 |
| Asthenia | 0 | 0 | 0 | 11 | 33 | 5 | 0 |
| Xerosis | 0 | 0 | 0 | 11 | 0 | 0 | 0 |
| Gastrointestinal infection | 0 | 0 | 0 | 11 | 0 | 0 | 0 |
| Bone pain | 0 | 0 | 0 | 22 | 17 | 0 | 0 |
| Arthralgia | 0 | 0 | 0 | 11 | 50 | 5 | 0 |
| Musculoskeletal chest pain | 0 | 0 | 0 | 11 | 0 | 0 | 0 |
| Myalgia | 0 | 0 | 0 | 11 | 0 | 0 | 100 |
| Dizziness | 0 | 0 | 0 | 22 | 0 | 5 | 0 |
| Headache | 0 | 0 | 0 | 11 | 0 | 5 | 0 |
| Anxiety | 0 | 0 | 0 | 11 | 0 | 0 | 0 |
| Rales | 0 | 0 | 0 | 11 | 0 | 0 | 0 |
| Nail disorder | 0 | 0 | 0 | 11 | 0 | 0 | 0 |
| Rash | 0 | 0 | 0 | 11 | 0 | 0 | 0 |
| Hot flush | 0 | 0 | 0 | 11 | 0 | 0 | 0 |
| Vertigo | 0 | 0 | 0 | 0 | 17 | 0 | 0 |
| Constipation | 0 | 0 | 0 | 0 | 17 | 16 | 0 |
| Flatulence | 0 | 0 | 0 | 0 | 17 | 11 | 0 |
| Gastric disorder | 0 | 0 | 0 | 0 | 17 | 0 | 0 |
| Hypersensitivity | 0 | 0 | 0 | 0 | 17 | 0 | 0 |
| Viral infection | 0 | 0 | 0 | 0 | 17 | 0 | 0 |
| Musculoskeletal pain | 0 | 0 | 0 | 0 | 17 | 5 | 0 |
| Balance disorder | 0 | 0 | 0 | 0 | 17 | 0 | 0 |
| Carpal tunnel syndrome | 0 | 0 | 0 | 0 | 17 | 0 | 0 |
| Sciatica | 0 | 0 | 0 | 0 | 17 | 0 | 0 |
| Dysuria | 0 | 0 | 0 | 0 | 17 | 0 | 0 |
| Dyspnoea | 0 | 0 | 0 | 0 | 33 | 0 | 0 |
| Rash maculo-papular | 0 | 0 | 0 | 0 | 17 | 0 | 0 |
| Sinus tachycardia | 0 | 0 | 0 | 0 | 0 | 5 | 0 |
| Eye pain | 0 | 0 | 0 | 0 | 0 | 5 | 0 |
| Visual impairment | 0 | 0 | 0 | 0 | 0 | 5 | 0 |
| Abdominal distension | 0 | 0 | 0 | 0 | 0 | 5 | 0 |
| Gastrointestinal haemorrhage | 0 | 0 | 0 | 0 | 0 | 5 | 0 |
| Adverse drug reaction | 0 | 0 | 0 | 0 | 0 | 5 | 0 |
| Chest pain | 0 | 0 | 0 | 0 | 0 | 5 | 0 |
| Chills | 0 | 0 | 0 | 0 | 0 | 5 | 0 |
| Hepatic pain | 0 | 0 | 0 | 0 | 0 | 5 | 0 |
| Urinary tract infection | 0 | 0 | 0 | 0 | 0 | 5 | 0 |
| Weight decreased | 0 | 0 | 0 | 0 | 0 | 11 | 0 |
| Hyperglycaemia | 0 | 0 | 0 | 0 | 0 | 5 | 0 |
| Muscular weakness | 0 | 0 | 0 | 0 | 0 | 11 | 0 |
| Back pain | 0 | 0 | 0 | 0 | 0 | 5 | 0 |
| Joint swelling | 0 | 0 | 0 | 0 | 0 | 5 | 0 |
| Dysgeusia | 0 | 0 | 0 | 0 | 0 | 5 | 0 |
| Peripheral sensory neuropathy | 0 | 0 | 0 | 0 | 0 | 5 | 0 |
| Insomnia | 0 | 0 | 0 | 0 | 0 | 11 | 0 |
| Haematuria | 0 | 0 | 0 | 0 | 0 | 5 | 0 |
| Incontinence | 0 | 0 | 0 | 0 | 0 | 5 | 0 |
| Cough | 0 | 0 | 0 | 0 | 0 | 5 | 0 |
| Alopecia | 0 | 0 | 0 | 0 | 0 | 5 | 0 |
| Dry skin | 0 | 0 | 0 | 0 | 0 | 5 | 0 |
| Pruritus | 0 | 0 | 0 | 0 | 0 | 5 | 0 |
| Conjunctivitis | 0 | 0 | 0 | 0 | 0 | 0 | 100 |
| Haemoptysis | 0 | 0 | 0 | 0 | 0 | 0 | 100 |
Clinically relevant abnormalities for Vital Signs (systolic blood pressure, diastolic blood pressure, and pulse rate). New abnormal findings or worsening of baseline conditions were reported as Adverse Events.
| percentage of participants | 50mg QD | 200mg QD | 100mg BID | 150mg BID | 200mg BID | 250mg BID | 300mg BID |
|---|---|---|---|---|---|---|---|
| Clinically Relevant Abnormalities for Vital Signs | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Cpre,ss represents the pre-dose concentration of Nintedanib in Plasma at steady-state at day 29
| ng/mL | 50mg QD | 200mg QD | 100mg BID | 150mg BID | 200mg BID | 250mg BID | 300mg BID |
|---|---|---|---|---|---|---|---|
| Pre-dose Concentration of Nintedanib in Plasma at Steady-state (Cpre,ss) | — | — | — | 7.54 ± 48.3 | 11.8 ± 33.5 | 11.0 ± 48.5 | — |
Unconfirmed best overall response assessed by RECIST (Response Evaluation Criteria In Solid Tumours) criteria (version 1.0). PD = Progressive disease.
| percentage of participants | 50mg QD | 200mg QD | 100mg BID | 150mg BID | 200mg BID | 250mg BID | 300mg BID |
|---|---|---|---|---|---|---|---|
| Complete response | 0 | 100 | 0 | 0 | 0 | 0 | 0 |
| Partial response | 0 | 0 | 0 | 0 | 0 | 5 | 0 |
| Stable disease | 100 | 0 | 75 | 33 | 0 | 16 | 0 |
| Non-evaluable, clinically non-progressive disease | 0 | 0 | 25 | 11 | 83 | 5 | 0 |
| PD or non-evaluable , clinically PD | 0 | 0 | 0 | 11 | 17 | 32 | 100 |
| Unknown | 0 | 0 | 0 | 44 | 0 | 42 | 0 |
Unconfirmed best objective response assessed by RECIST (Response Evaluation Criteria In Solid Tumours) criteria (version 1.0)
| percentage of participants | 50mg QD | 200mg QD | 100mg BID | 150mg BID | 200mg BID | 250mg BID | 300mg BID |
|---|---|---|---|---|---|---|---|
| No | 100 | 0 | 100 | 56 | 100 | 53 | 100 |
| Yes | 0 | 100 | 0 | 0 | 0 | 5 | 0 |
| Unknown | 0 | 0 | 0 | 44 | 0 | 42 | 0 |
Clinical benefit was defined as the absence of disease progression (no PD or nonevaluable clinically progressive disease) determined by RECIST (version 1.0).
| percentage of participants | 50mg QD | 200mg QD | 100mg BID | 150mg BID | 200mg BID | 250mg BID | 300mg BID |
|---|---|---|---|---|---|---|---|
| No | 0 | 0 | 0 | 0 | 0 | 11 | 0 |
| Yes | 100 | 100 | 100 | 100 | 100 | 89 | 100 |
Confirmed objective response assessed by RECIST (Response Evaluation Criteria In Solid Tumours) criteria (version 1.0)
| percentage of participants | 50mg QD | 200mg QD | 100mg BID | 150mg BID | 200mg BID | 250mg BID | 300mg BID |
|---|---|---|---|---|---|---|---|
| No | 100 | 0 | 100 | 56 | 100 | 58 | 100 |
| Yes | 0 | 100 | 0 | 0 | 0 | 0 | 0 |
| Unknown | 0 | 0 | 0 | 44 | 0 | 42 | 0 |
Percentage of participants that experienced progression free survival (PFS), assessed by RECIST (Response Evaluation Criteria In Solid Tumours) (version 1.0), by day 1230. Progression was defined as progressive disease (PD) or non-evaluable clinically progressive disease. PFS was defined for patients without PD at screening as the time from first treatment with the trial drug in the previous trial until onset of PD or death, whatever comes earlier. Patients with PD could enter the trial if they showed signs of clinical benefit. For patients with PD at screening, the RECIST assessment at screening was used as a new baseline value and PFS was the time from first treatment with the trial drug in this trial until the onset of progressive disease in this trial or death, whatever comes first.
| percentage of participants | 50mg QD | 200mg QD | 100mg BID | 150mg BID | 200mg BID | 250mg BID | 300mg BID |
|---|---|---|---|---|---|---|---|
| Progression (RECIST) | 0 | 100 | 25 | 11 | 33 | 42 | 100 |
| Death | 0 | 0 | 0 | 0 | 0 | 32 | 0 |
| No progressive disease (RECIST) or death | 100 | 0 | 75 | 44 | 67 | 16 | 0 |
| Unknown | 0 | 0 | 0 | 45 | 0 | 10 | 0 |
All patients who had grade 2 adverse events (AEs) as the worst grade of the AE. Incidence and intensity of Adverse Events with grading of Adverse Events according to Common Terminology Criteria for Adverse Events (CTCAE).
| percentage of participants | 50mg QD | 200mg QD | 100mg BID | 150mg BID | 200mg BID | 250mg BID | 300mg BID |
|---|---|---|---|---|---|---|---|
| Fatigue | 0 | 0 | 0 | 22 | 0 | 11 | 0 |
| Anorexia | 0 | 0 | 0 | 0 | 0 | 11 | 0 |
| Diarrhoea | 0 | 0 | 0 | 11 | 33 | 21 | 0 |
| Bronchitis | 0 | 0 | 0 | 0 | 17 | 0 | 0 |
| Nausea | 0 | 0 | 0 | 0 | 0 | 11 | 0 |
| Vomiting | 0 | 0 | 0 | 0 | 0 | 5 | 0 |
| Abdominal pain | 0 | 0 | 0 | 11 | 0 | 0 | 0 |
| Asthenia | 0 | 0 | 25 | 11 | 0 | 11 | 0 |
| Gastrointestinal infection | 0 | 0 | 0 | 0 | 17 | 0 | 0 |
| Bone pain | 0 | 0 | 0 | 0 | 0 | 11 | 0 |
| Arthralgia | 0 | 0 | 0 | 0 | 0 | 5 | 0 |
| Musculoskeletal chest pain | 0 | 0 | 0 | 11 | 0 | 0 | 0 |
| Headache | 0 | 0 | 25 | 11 | 0 | 0 | 0 |
| Constipation | 0 | 0 | 0 | 0 | 0 | 5 | 0 |
| Flatulence | 0 | 0 | 0 | 11 | 0 | 0 | 0 |
| Musculoskeletal pain | 0 | 0 | 0 | 0 | 0 | 5 | 0 |
| Sciatica | 0 | 0 | 0 | 0 | 0 | 11 | 0 |
| Dyspnoea | 0 | 0 | 0 | 11 | 0 | 11 | 0 |
| Chest pain | 0 | 0 | 0 | 11 | 0 | 0 | 0 |
| Urinary tract infection | 0 | 0 | 25 | 0 | 0 | 5 | 0 |
| Weight decreased | 0 | 0 | 0 | 0 | 0 | 5 | 0 |
| Back pain | 0 | 0 | 0 | 11 | 0 | 0 | 0 |
| Peripheral sensory neuropathy | 0 | 0 | 0 | 0 | 17 | 0 | 0 |
| Cough | 0 | 0 | 0 | 0 | 0 | 11 | 0 |
| Haemoptysis | 0 | 0 | 0 | 0 | 0 | 5 | 0 |
| Osteoarthritis | 0 | 0 | 25 | 0 | 0 | 0 | 0 |
| Parotitis | 0 | 0 | 0 | 11 | 0 | 0 | 0 |
| Osteolysis | 0 | 0 | 0 | 11 | 0 | 0 | 0 |
| Abdominal pain upper | 0 | 0 | 0 | 0 | 17 | 0 | 0 |
| Gastrointestinal disorder | 0 | 0 | 0 | 0 | 17 | 0 | 0 |
| Groin pain | 0 | 0 | 0 | 0 | 17 | 0 | 0 |
| Anaemia | 0 | 0 | 0 | 0 | 0 | 5 | 0 |
| Neutropenia | 0 | 0 | 0 | 0 | 0 | 5 | 0 |
| Oedema peripheral | 0 | 0 | 0 | 0 | 0 | 5 | 0 |
| Gamma-glutamyltransferase increased | 0 | 0 | 0 | 0 | 0 | 5 | 0 |
| Dehydration | 0 | 0 | 0 | 0 | 0 | 5 | 0 |
| Productive cough | 0 | 0 | 0 | 0 | 0 | 5 | 0 |
| Deep vein thrombosis | 0 | 0 | 0 | 0 | 0 | 5 | 0 |
| Phlebitis superficial | 0 | 0 | 0 | 0 | 0 | 5 | 0 |
All patients who had grade 3 adverse events (AEs) as the worst grade of the AE. Incidence and intensity of Adverse Events with grading of Adverse Events according to Common Terminology Criteria for Adverse Events (CTCAE).
| percentage of participants | 50mg QD | 200mg QD | 100mg BID | 150mg BID | 200mg BID | 250mg BID | 300mg BID |
|---|---|---|---|---|---|---|---|
| Gamma-glutamyltransferase increased | 100 | 0 | 0 | 0 | 0 | 0 | 0 |
| Diarrhoea | 0 | 0 | 25 | 11 | 0 | 5 | 0 |
| Diarrhoea infectious | 0 | 0 | 25 | 0 | 0 | 0 | 0 |
| Dyspnoea | 0 | 0 | 0 | 11 | 0 | 5 | 0 |
| Lymphopenia | 0 | 0 | 0 | 0 | 0 | 5 | 0 |
| Constipation | 0 | 0 | 0 | 0 | 0 | 5 | 0 |
| Haemorrhoids | 0 | 0 | 0 | 0 | 0 | 5 | 0 |
| Ileus | 0 | 0 | 0 | 0 | 0 | 5 | 0 |
| Subileus | 0 | 0 | 0 | 0 | 0 | 5 | 0 |
| Vomiting | 0 | 0 | 0 | 0 | 0 | 5 | 0 |
| Pneumonia | 0 | 0 | 0 | 0 | 0 | 5 | 0 |
| Convulsion | 0 | 0 | 0 | 0 | 0 | 5 | 0 |
| Renal failure | 0 | 0 | 0 | 0 | 0 | 11 | 0 |
| Urinary tract obstruction | 0 | 0 | 0 | 0 | 0 | 5 | 0 |
| Pleural effusion | 0 | 0 | 0 | 0 | 0 | 5 | 0 |
All patients who had grade 4 adverse events (AEs) as the worst grade of the AE. Incidence and intensity of Adverse Events with grading of Adverse Events according to Common Terminology Criteria for Adverse Events (CTCAE).
| percentage of participants | 50mg QD | 200mg QD | 100mg BID | 150mg BID | 200mg BID | 250mg BID | 300mg BID |
|---|---|---|---|---|---|---|---|
| Incidence and Intensity of Adverse Events With Highest CTCAE Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
All patients who had grade 5 adverse events (AEs) as the worst grade of the AE. Incidence and intensity of Adverse Events with grading of Adverse Events according to Common Terminology Criteria for Adverse Events (CTCAE).
| percentage of participants | 50mg QD | 200mg QD | 100mg BID | 150mg BID | 200mg BID | 250mg BID | 300mg BID |
|---|---|---|---|---|---|---|---|
| Subdural Haematoma | 0 | 0 | 0 | 0 | 0 | 5 | 0 |
| Malignant neoplasm progression | 0 | 0 | 0 | 0 | 0 | 26 | 0 |
Difference from baseline (normalized value). Baseline was defined as the value at the time point closest to but prior to very first administration of trial medication. The standard error is actually the Interquartile Range calculated as P75 minus P25.
| U/L | 50mg QD | 200mg QD | 100mg BID | 150mg BID | 200mg BID | 250mg BID | 300mg BID |
|---|---|---|---|---|---|---|---|
| Alkaline phosphatase | 127.0 ± 0.0 | 11.9 ± 0.0 | -39.0 ± 70.5 | -21.2 ± 96.4 | -11.7 ± 81.0 | 16.0 ± 180.9 | 7.2 ± 0.0 |
| Aspartate aminotransferase | 14.3 ± 0.0 | 13.7 ± 0.0 | 9.6 ± 18.0 | 6.8 ± 9.1 | 4.3 ± 41.0 | 15.9 ± 35.1 | 7.6 ± 0.0 |
| Alanine aminotransferase | 10.6 ± 0.0 | 6.6 ± 0.0 | 0.6 ± 11.1 | -1.6 ± 18.8 | 9.1 ± 45.4 | 17.0 ± 33.6 | 12.4 ± 0.0 |
Difference from baseline (normalized value). Baseline was defined as the value at the time point closest to but prior to very first administration of trial medication. The standard error is actually the Interquartile Range calculated as P75 minus P25.
| mg/dL | 50mg QD | 200mg QD | 100mg BID | 150mg BID | 200mg BID | 250mg BID | 300mg BID |
|---|---|---|---|---|---|---|---|
| Bilirubin (total) | 0.5 ± 0.0 | 0.0 ± 0.0 | 0.0 ± 0.2 | 0.0 ± 0.3 | 0.1 ± 0.1 | 0.1 ± 0.3 | 0.0 ± 0.0 |
| Creatinine | -0.1 ± 0.0 | -0.3 ± 0.0 | 0.0 ± 0.2 | -0.1 ± 0.0 | -0.1 ± 0.2 | -0.1 ± 0.3 | 0.0 ± 0.0 |
| Glucose (N=1,1,3,9,4,14,1) | -60.0 ± 0.0 | -2.2 ± 0.0 | 28.9 ± 126.1 | -11.3 ± 75.1 | -76.5 ± 75.9 | -23.3 ± 52.2 | -40.0 ± 0.0 |
Difference from baseline for Haemoglobin (normalized value). Baseline was defined as the value at the time point closest to but prior to very first administration of trial medication. The standard error is actually the Interquartile Range calculated as P75 minus P25.
| g/dL | 50mg QD | 200mg QD | 100mg BID | 150mg BID | 200mg BID | 250mg BID | 300mg BID |
|---|---|---|---|---|---|---|---|
| Difference From Baseline for Haemoglobin | -1.8 ± 0.0 | 1.4 ± 0.0 | 0.4 ± 2.3 | 1.0 ± 1.3 | 1.2 ± 0.7 | -0.2 ± 2.1 | 1.1 ± 0.0 |
Difference from baseline (normalized value). Baseline was defined as the value at the time point closest to but prior to very first administration of trial medication. The standard error is actually the Interquartile Range calculated as P75 minus P25.
| 10^9 /L | 50mg QD | 200mg QD | 100mg BID | 150mg BID | 200mg BID | 250mg BID | 300mg BID |
|---|---|---|---|---|---|---|---|
| Platelets | 42.2 ± 0.0 | 11.1 ± 0.0 | 1.0 ± 83.7 | -2.5 ± 25.2 | -38.1 ± 39.9 | 11.2 ± 65.9 | -27.1 ± 0.0 |
| White blood cell count | -1.1 ± 0.0 | -0.7 ± 0.0 | 0.2 ± 2.9 | -0.8 ± 2.6 | -0.1 ± 5.6 | 0.7 ± 2.9 | 0.0 ± 0.0 |
| Lymphocytes (N=1,1,4,9,4,17,1) | -0.6 ± 0.0 | -0.4 ± 0.0 | -0.1 ± 2.0 | 1.0 ± 1.1 | 0.0 ± 1.6 | 0.6 ± 0.6 | 1.1 ± 0.0 |
| Neutrophils (N=1,1,4,9,6,17,1) | -4.1 ± 0.0 | -4.7 ± 0.0 | 0.9 ± 3.7 | -1.0 ± 5.6 | -2.4 ± 10.0 | -0.5 ± 3.0 | -1.2 ± 0.0 |
Difference from baseline (normalized value) in coagulation parameters Prothrombin time, international normalised ratio (PT-INR) and partial thromboplastin time. Baseline was defined as the value at the time point closest to but prior to very first administration of trial medication. The standard error is actually the Interquartile Range calculated as P75 minus P25.
| sec | 50mg QD | 200mg QD | 100mg BID | 150mg BID | 200mg BID | 250mg BID | 300mg BID |
|---|---|---|---|---|---|---|---|
| PT-INR (N=1,1,3,7,5,14,1) | 0.1 ± 0.0 | 0.1 ± 0.0 | 0.3 ± 0.6 | 0.1 ± 0.1 | 0.2 ± 0.5 | -0.0 ± 0.1 | 0.1 ± 0.0 |
| Partial thromboplastin time (N=1,1,3,9,4,14,1) | 0.7 ± 0.0 | 2.6 ± 0.0 | -3.6 ± 6.7 | 1.9 ± 4.3 | 1.9 ± 4.3 | 1.5 ± 4.7 | -2.9 ± 0.0 |
Difference from baseline (normalized value). Baseline was defined as the value at the time point closest to but prior to very first administration of trial medication. The standard error is actually the Interquartile Range calculated as P75 minus P25.
| mmol/L | 50mg QD | 200mg QD | 100mg BID | 150mg BID | 200mg BID | 250mg BID | 300mg BID |
|---|---|---|---|---|---|---|---|
| Potassium (N=1,1,4,9,6,18,1) | 0.2 ± 0.0 | -0.3 ± 0.0 | -0.3 ± 2.1 | 0.1 ± 0.4 | -0.0 ± 1.1 | 0.1 ± 0.9 | 0.0 ± 0.0 |
| Sodium (N=1,1,4,9,6,18,1) | 2.0 ± 0.0 | 1.0 ± 0.0 | 3.3 ± 5.2 | 0.0 ± 1.5 | 1.5 ± 6.0 | -1.3 ± 5.5 | 5.0 ± 0.0 |
Collected over From the first intake of trial medication until 28 days after last intake of medication, up to 1119 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 50mg QD | — | 0/1 (0%) | 1/1 (100%) |
| 200mg QD | — | 0/1 (0%) | 1/1 (100%) |
| 100mg BID | — | 0/4 (0%) | 4/4 (100%) |
| 150mg BID | — | 1/9 (11.1%) | 9/9 (100%) |
| 200mg BID | — | 0/6 (0%) | 6/6 (100%) |
| 250mg BID | — | 9/19 (47.4%) | 17/19 (89.5%) |
| 300mg BID | — | 0/1 (0%) | 1/1 (100%) |
| Event | 50mg QD | 200mg QD | 100mg BID | 150mg BID | 200mg BID | 250mg BID | 300mg BID |
|---|---|---|---|---|---|---|---|
| Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/1 | 0/1 | 0/4 | 0/9 | 0/6 | 5/19 | 0/1 |
| OsteolysisMusculoskeletal and connective tissue disorders | 0/1 | 0/1 | 0/4 | 1/9 | 0/6 | 0/19 | 0/1 |
| ConstipationGastrointestinal disorders | 0/1 | 0/1 | 0/4 | 0/9 | 0/6 | 2/19 | 0/1 |
| Renal failureRenal and urinary disorders | 0/1 | 0/1 | 0/4 | 0/9 | 0/6 | 2/19 | 0/1 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/1 | 0/1 | 0/4 | 0/9 | 0/6 | 2/19 | 0/1 |
| IleusGastrointestinal disorders | 0/1 | 0/1 | 0/4 | 0/9 | 0/6 | 1/19 | 0/1 |
| SubileusGastrointestinal disorders | 0/1 | 0/1 | 0/4 | 0/9 | 0/6 | 1/19 | 0/1 |
| VomitingGastrointestinal disorders | 0/1 | 0/1 | 0/4 | 0/9 | 0/6 | 1/19 | 0/1 |
| PneumoniaInfections and infestations | 0/1 | 0/1 | 0/4 | 0/9 | 0/6 | 1/19 | 0/1 |
| Urinary tract infectionInfections and infestations | 0/1 | 0/1 | 0/4 | 0/9 | 0/6 | 1/19 | 0/1 |
| Event | 50mg QD | 200mg QD | 100mg BID | 150mg BID | 200mg BID | 250mg BID | 300mg BID |
|---|---|---|---|---|---|---|---|
| ConjunctivitisEye disorders | 0/1 | 0/1 | 0/4 | 0/9 | 0/6 | 0/19 | 1/1 |
| DiarrhoeaGastrointestinal disorders | 0/1 | 1/1 | 1/4 | 6/9 | 5/6 | 12/19 | 1/1 |
| DyspepsiaGastrointestinal disorders | 1/1 | 0/1 | 0/4 | 1/9 | 0/6 | 0/19 | 0/1 |
| FatigueGeneral disorders | 1/1 | 0/1 | 0/4 | 5/9 | 1/6 | 2/19 | 0/1 |
| BronchitisInfections and infestations | 0/1 | 1/1 | 0/4 | 0/9 | 1/6 | 0/19 | 0/1 |
| NasopharyngitisInfections and infestations | 1/1 | 0/1 | 0/4 | 0/9 | 2/6 | 1/19 | 0/1 |
| Gamma-glutamyltransferase increasedInvestigations | 1/1 | 0/1 | 0/4 | 0/9 | 0/6 | 1/19 | 0/1 |
| AnorexiaMetabolism and nutrition disorders | 1/1 | 0/1 | 0/4 | 1/9 | 0/6 | 5/19 | 0/1 |
| MyalgiaMusculoskeletal and connective tissue disorders | 0/1 | 0/1 | 0/4 | 1/9 | 0/6 | 0/19 | 1/1 |
| HaemoptysisRespiratory, thoracic and mediastinal disorders | 0/1 | 0/1 | 0/4 | 0/9 | 0/6 | 1/19 | 1/1 |
Treated set which comprised of all patients who received at least one dose of Nintedanib in both their previous Nintedanib trial and in this extension trial
| Age, Continuous(years) | 50mg QD | 200mg QD | 100mg BID | 150mg BID | 200mg BID | 250mg BID | 300mg BID | Total |
|---|---|---|---|---|---|---|---|---|
| Median | 75.0 (75 to 75) | 47.0 (47 to 47) | 65.5 (52 to 75) | 66.0 (52 to 78) | 63.5 (45 to 74) | 66.0 (41 to 80) | 67.0 (67 to 67) | 66.0 (41 to 80) |
| Sex: Female, Male(Participants) | 50mg QD | 200mg QD | 100mg BID | 150mg BID | 200mg BID | 250mg BID | 300mg BID | Total |
|---|---|---|---|---|---|---|---|---|
| Female | 0 | 1 | 2 | 2 | 2 | 1 | 0 | 8 |
| Male | 1 | 0 | 2 | 7 | 4 | 18 | 1 | 33 |
The record gives a start of Oct 2004 and a primary completion of Sep 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2014, 5 years 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nintedanib